Protagonist Therapeutics

Youtube Subscribe

Open: 24.97 Close: 25.37 Change: 0.4

How to know if Protagonist Therapeutics Company Inc is a risky investment without reading the whole internet.

How much time have you spent trying to decide whether investing in Protagonist Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Protagonist Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Protagonist Therapeutics, Inc. develops peptide-based drugs for hematology and blood disorders. Rusfertide (PTG-300) is in Phase II clinical trials for the treatment of erythrocyt.

Today's Summary

Wall Street analysts expect a potential upside of 322.3% in Protagonist Therapeutics (PTGX) The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics. Insider Transactions Bought Shares Worth $5.4K over the last 3 months.

Today's News

Protagonist Therapeutics and Janssen Biotech collaboration shows promise for oral therapy for IL-23-mediated diseases. JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis. Wall Street analysts expect a potential upside of 322.3% in Protagonist Therapeutics (PTGX) The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics. The average of price targets set by Wall Street analyst suggests a potential upside of 322.4%. Protagonist Therapeutics shares are trading lower after the company announced pricing of a $100 million public offering of shares of common stock. Insider Transactions Bought Shares Worth $5.4K over the last 3 months. Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference. Protagonist is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 in advanced stages of clinical development. The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of the company. Market value can be influenced by many factors that dont directly affect the companys underlying business (such as a pandemic or basic market pessimism) Protagonist Therapeutics stock opened at $25.02 on Wednesday. JMP Securities decreased their target price on ProtagonistTherapeutics from $31.00 to $28.00 and set a “market outperform” rating for the company. State Street Corp lifted its holdings in shares of Protagonist. by 108.1% during the 2nd quarter. Morgan Stanley raised its stake in shares. of Prot Groups to which one successful PHI hook staffer Sourceschanges famously The revised Q2 2023 EPS estimate for Protagonist Therapeutics is a reassuring sign not only for current shareholders but also for potential investors looking to get on board.

Stock Profile

"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California."

Keywords

The game is changing. There is a new strategy to evaluate Protagonist Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Protagonist Therapeutics are: Protagonist, Therapeutics, company, potential, price, share, value, and the most common words in the summary are: therapeutic, company, protagonist, inc, biopharmaceutical, johnson, entrada, . One of the sentences in the summary was: Wall Street analysts expect a potential upside of 322.3% in Protagonist Therapeutics (PTGX) The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #company #protagonist #inc #biopharmaceutical #johnson #entrada.

Read more →

Youtube Subscribe

---